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1198Objective: Endoscopic treatment of superficial esophageal carcinoma has been increasingly conducted around
the world. Because no lymph nodes are removed in such a procedure, the risk of lymph node metastases (LNMs)
should be clearly understood. The aim of the present study was to accurately clarify the pattern of lymphatic
spread in patients with superficial esophageal squamous cell carcinoma and analyze the factors potentially
related to LNMs.
Methods: The pattern of lymphatic spread was studied in 189 patients who had undergone radical lymphade-
nectomy from 2006 to 2011. The risk factors associated with LNMs were determined by multivariate logistic
regression analysis. According to the depth of tumor invasion, mucosal tumors were classified as M1, M2,
and M3 and submucosal tumors as SM1, SM2, and SM3.
Results: A total of 4252 lymph nodes were resected (average, 23  9; range, 12-68). LNMs occurred in 49
patients (25.9%). The frequency of LNMswas 4.3% in thosewith mucosal and 33.1% in thosewith submucosal
cancer. LNMs were found in 0%, 0%, 11.8%, 24.0%, 20.5%, and 43.8% of the M1, M2, M3, SM1, SM2, and
SM3 cancer, respectively. For submucosal cancer, SM3 cancer (P ¼ .006) and lymphovascular invasion
(P ¼ .001) were significant independent risk factors for LNMs. Paratracheal nodes were the most frequently
involved. ‘‘Skip’’ metastases occurred in 20 of 49 patients (40.8%).
Conclusions: Endoscopic treatment can be attempted when the tumor is limited to the lamina propria mucosa.
However, 2-field radical lymphadenectomy with careful upper mediastinal lymph node resection should be
conducted for submucosal squamous cell carcinoma. (J Thorac Cardiovasc Surg 2013;146:1198-203)Earn CME credits at
http://cme.ctsnetjournals.org
Superficial esophageal cancer (SEC), defined as intraepithe-
lial (Tis), mucosal (T1a), and submucosal (T1b) cancer,
regardless of lymph node status, implies a better prognosis
owing to an early tumor stage.1 Traditionally, esophagectomy
with radical lymphadenectomy has been considered the best
curative treatment for such patients. However, this procedure
carries significant long-termmorbidity.2-4 To achieve a better
postoperative quality of life, a trend has occurred toward
endoscopic treatment of superficial lesions.5,6 Nonetheless,
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The Journal of Thoracic and Cardiovascular Surexists, because of the abundant lymph–capillary plexus in
the lamina propria mucosa and submucosa of the
esophagus. At present, treatment of SEC remains somewhat
controversial, including the most appropriate criteria for
endoscopic therapy, patient selection for esophagectomy,
and extent of lymphadenectomy.3,4,7-10 Because no lymph
nodes are removed during endoscopic therapy and radical
lymphadenectomy to remove all potentially involved nodes
is thought to be essential for curative treatment, it is
important to assess the likelihood of LNMs in the
management of the disease.
The present study represents the first series of SEC from
China, where squamous cell carcinoma (SCC) is the predom-
inant pathologic type. The aim of the present retrospective
study was to accurately document the pattern of LNMs in
superficial SCC and to study the potential associated factors.METHODS
Patients
The institutional review board of Fudan University Shanghai Cancer
Center approved the present retrospective study. From January 2006 to
December 2011, 2069 patients underwent esophagectomy at our center.
The patient inclusion criteria for our retrospective study were as follows:
(1) thoracic superficial SCC (Tis and T1); (2) radical lymphadenectomy
through a thoracotomy; (3) 12 or more removed lymph nodes11; (4) no
chemotherapy or radiotherapy before surgery; and (5) specimens available
for repeat review (Figure 1). A total of 189 patients met the inclusiongery c November 2013
FIGURE 1. Patient disposition chart.
Abbreviations and Acronyms
3-FL ¼ 3-field lymphadenectomy
LNM ¼ lymph node metastasis
SCC ¼ squamous cell carcinoma
SEC ¼ superficial esophageal cancer
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female ratio of 3.2:1, and in-hospital mortality of 0.5% (1 of 189).
Preoperative Workup
According to the practice guidelines of the Fudan University Shanghai
Cancer Center, the preoperative workup included a complete history,
physical examination, endoscopy of the entire upper gastrointestinal tract,
and histologic confirmation of the carcinoma. Computed tomography of
the chest, ultrasonography or computed tomography of the abdomen, and
the neck were performed to evaluate the resectability of the tumor and to
exclude distant metastases.
Surgical Procedure
Surgery with curative intent involved resection of the primary cancer
with negative microscopic resection margins and radical lymphadenec-
tomy. The McKeown procedure, Ivor-Lewis procedure, and Sweet
procedure were the 3 most common surgery types. Details of the resection
techniques have been previously described.2 In brief, total mediastinal
lymphadenectomywas routinely performed through a right-sided approach
(McKeown procedure for upper esophageal tumors and Ivor-Lewis
procedure for middle and lower tumors), and on the left using the
Sweet procedure for lower esophageal tumors. Only the lymph nodes in
the middle and lower mediastinum were removed because of the
anatomic limitations. A gastric conduit was used for reconstruction in all
patients. Cervical lymphadenectomy through a collar incisionwas included
when nodal involvement was suggested by ultrasound or computed
tomography.Lymph Node Classification
Lymph node sites were classified according to the nomenclature and
code number of the Japanese Society for Esophageal Disease.12 Cervical
nodes included those in the cervical paraesophageal (no. 101) and supracla-
vicular regions (no. 104). The upper mediastinal nodes included the upper
paraesophageal (no. 105) and paratracheal nodes (no.106r and 106tb). The
middle mediastinal nodes included the subcarinal (no. 107), middle
paraesophageal (no. 108), and bilateral hilar lymph nodes (no. 109). The
lower mediastinal nodes included the lower paraesophageal (no. 110),
posterior mediastinal lymph (no. 111), and diaphragmatic nodes
(no. 112). The upper abdominal nodes included the nodes lateral to the
paracardia, lesser curvature, greater curvature, left gastric, common
hepatic, splenic, and celiac regions.
Histopathologic Assessment
The esophageal resection specimens were histopathologically assessed
by experienced pathologists using a standardized protocol in which the site
and size of the primary cancer, sample margins, and involvement of
regional lymph nodeswere recorded, in addition to the presence of lympho-
vascular invasion. Because subdivision of SEC is not routinely performed
at our center, all SEC specimens were reviewed again by a pathologist
(Y.K.), who was unaware of the previous pathologic reports, and subclas-
sified into 6 layers according to the depth of invasion1: epithelium (M1),
superficial layer of the lamina propria mucosa (M2), deeper layer of theThe Journal of Thoracic and Carlamina propria mucosa (M3), superficial layer of the submucosa (SM1),
middle layer of the submucosa (SM2), and deeper layer of the submucosa
(SM3).
Statistical Analysis
Statistical analysis was performed using the Statistical Package for
Social Sciences statistical software, version 16.0 (SPSS, Chicago, Ill). A
nomogram and bootstrapping were done with R, version 2.10.0. The stan-
dard chi-square test or Fisher’s exact test was used for comparative anal-
ysis. Univariate and multivariate logistical regression analyses were
performed to identify the factors associated with LNMs. The results
were considered significant at P<.05.
RESULTS
All patients underwent curative R0 resection, of whom 23
underwent 3-field lymphadenectomy (3-FL), and 166
underwent 2-field lymphadenectomy. A total of 4252 lymph
nodes were resected (average, 23 9; range, 12-68). Of the
4252 lymph nodes resected, 107 (2.5%) were positive in
49 of the 189 patients (25.9%), including 2 of 47 patients
(4.3%) with mucosal and 47 of 142 (33.1%) with submuco-
sal cancer.
Cancer Characteristics
For analysis, the patients were divided into mucosal
(M1, M2, M3) and submucosal (SM1, SM2 SM3) groups.
The depth of invasion was M1 in 21, M2 in 9, M3 in 17,
SM1 in 25, SM2 in 44, and SM3 in 73 patients. The baselinediovascular Surgery c Volume 146, Number 5 1199
TABLE 2. Submucosal tumors: frequency of lymph node metastases
according to tumor characteristics
Factor LNMs (%) P value
Tumor location .400
Upper 20.0 (4/20)
Middle 35.7 (30/84)
Lower 34.2 (13/38)
Tumor length (cm) .415
1 27.6 (8/29)
1-2 28.8 (19/66)
2-3 42.9 (12/28)
>3 42.1 (8/19)
Tumor differentiation .023
Well 26.7 (4/15)
Moderate 26.7 (24/90)
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tumor length, were comparable between the 2 groups. No
lymphovascular invasion was found in the mucosal tumors,
whereas more poorly differentiated tumors were present in
patients with submucosal tumors. Most patients (78.8%)
underwent radical 2-field lymphadenectomy through a
right thoracotomy. The surgery types were similar between
the 2 groups (Table 1). No LNMs occurred in patients
with M1 or M2 cancer, but 2 of 17 patients (11.8%) with
M3 cancer had LNMs. The frequency of LNM was
24.0%, 20.5%, and 43.8% for the SM1, SM2, and SM3
subgroups, respectively, with most submucosal cancers
with LNM presenting with only 1 or 2 positive nodes
(74.5%, 35 of 47 cases).Poor 51.4 (19/37)
Lymphovascular invasion <.001
No 28.5 (37/130)
Yes 83.3 (10/12)Risk Factors for LNMs in Submucosal Cancer
Of the 142 patients with submucosal cancer, poor
differentiation, lymphovascular invasion, and SM3 cancerTABLE 1. Patient characteristics according to tumor invasion depth
Characteristic
Mucosal
(n ¼ 47)
Submucosal
(n ¼ 142)
P
value
Gender .387
Male 38 (80.9) 106 (74.6)
Female 9 (19.1) 36 (25.7)
Age (y) .830
60 26 (55.3) 76 (53.5)
>60 21 (44.7) 66 (46.5)
Tumor location .357
Upper 3 (6.4) 20 (14.1)
Middle 29 (61.7) 84 (59.2)
Lower 15 (31.9) 38 (26.8)
Tumor length (cm) .515
2 29 (61.7) 95 (66.9)
>2 18 (38.3) 47 (33.1)
Differentiation <.001
Well 26 (55.3) 15 (10.6)
Moderate 21 (44.7) 90 (63.4)
Poor 0 (0.0) 37 (26.1)
LNM <.001
Negative 45 (95.7) 95 (66.9)
Positive 2 (4.3) 47 (33.1)
Lymphovascular invasion .040
Yes 0 (0.0) 12 (8.5)
No 47 (100.0) 130 (91.5)
Procedure type .260
Right thoracotomy (3-FL) 3 (6.4) 20 (14.1)
Right thoracotomy (2-FL) 38 (80.9) 111 (78.2)
Left thoracotomy (2-FL) 6 (12.8) 11 (7.7)
Subclassification of tumor
invasion
M1: 21 (44.7) SM1: 25 (17.6)
M2: 9 (19.1) SM2: 44 (31.0)
M3: 17 (36.2) SM3: 73 (51.4)
Data presented as n (%). LNM, Lymph node metastasis; 3-FL, 3-field lymphadenec-
tomy; 2-FL, 2-field lymphadenectomy; SM, submucosa.
Tumor invasion depth .005*
SM1 24.0 (6/25)
SM2 20.5 (9/44)
SM3 43.8 (32/73)
LNMs, Lymph node metastases; SM, submucosa. *SM3 tumors compared with SM1
and SM2 tumors.
1200 The Journal of Thoracic and Cardiovascular Surwere associated with greater LNM occurrence. A tendency
was seen for more LNM to occur as the tumor length
increased, but no significant difference was observed
(Table 2). Multivariate analysis identified SM3 cancer
(P ¼ .006) and lymphovascular invasion (P ¼ .001) as
independent LNM risk factors (Table 3). However, SM1
or SM2 cancers without lymphovascular invasion did not
exclude the possibility of LNMs. The prediction model is
presented as a nomogram that graphically shows the
multivariate effects of the risk factors (Figure 2). The
bootstrap-corrected c-index of the model was 0.74.Pattern of LNMs
For upper and middle submucosal cancer, LNM was
common in the upper mediastinum and abdomen. For lower
submucosal cancer, LNM was common in the lower
mediastinum and abdomen (Figure 3). For submucosal
cancers, paratracheal lymph nodes were the most frequently
involved (12.0%), followed by the lesser curvature
(10.6%), middle paraesophageal (5.6%), and paracardial
nodes (5.6%) (Figure 4).
‘‘Skip’’ metastases, referring to a patient with cervical
and/or abdominal involvement but no mediastinal
metastasis, occurred in 20 of 49 patients (40.8%). Of those
with skip metastases, 2 had M3 tumors. Positive LNMs
involving 2 regions were seen in 16.7% of SM1, 30% of
SM2, and 16.1% of SM3 tumors. Cervical metastases
were identified in only 1 of 23 patients (0.4%) with 3-FL
(Table 4).gery c November 2013
TABLE 3. Submucosal tumors: logistic analysis of risk factors for lymph node metastases
Variable
Univariate analysis Multivariate analysis
OR 95% CI P value OR 95% CI P value
Tumor depth 1.347-5.863 .006 1.361-6.550 .006
SM1/SM2 1 1
SM3 2.810 2.855
Lymphovascular invasion 2.672-60.122 .002 2.726-68.008 .001
No 1 1
Yes 12.568 13.615
Tumor length (cm) 0.899-3.872 .094 — — —
2 1
>2 1.866
Differentiation 1.336-6.309 .007 — — —
Well and moderate 1
Poor 2.903
OR, Odds ratio; CI, confidence interval; SM, submucosa.
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Esophageal cancer is the eighth most common cancer
and sixth most common cause of cancer-related death
in China.13 At diagnosis, most esophageal cancers are at
a locally advanced stage. However, because of wide-
spread endoscopic screening and advances in diagnostic
modalities, such as endoscopic mucosal resection and
endoscopic submucosal dissection, the incidence of SEC
in China is increasing. Thus, less invasive procedures
without lymphadenectomy, including endoscopic therapy,
have been increasingly performed. In contrast to the West,
where adenocarcinoma is the major pathologic type, SCC
is the predominate type in China. Because the lymph
node status is one of the most important factors in predicting
the prognosis for patients with esophageal SCC, it is crucialFIGURE 2. Nomogram predicting risk of lymph node metastases in submucos
of lymph node metastases, locate the patient values on each axis. Draw a vertical
variable. Sum the points for all the variables. Locate the sum on the total po
SM, Submucosa.
The Journal of Thoracic and Carto know the risk of LNMs for the management of SEC.
Therefore, in the present study, we aimed to accurately
document the incidence of LNMs and study the factors
associated with LNMs in patients with superficial SCC.
Our results also showed that LNM was rare when the
cancer was confined to the mucosa (4.3%, a rate similar
to previous reports7,14). No LNM was observed in patients
with M1 or M2 tumors; therefore, endoscopic resection
can be indicated for such patients. However, in patients
with M3 tumors, LNMs were found in 2 of 17 patients, 1
of whom had 2 positive lymph nodes in the mediastinum
and 1 of who had 3 in the abdomen. Both tumors were
moderately differentiated and without lymphovascular
invasion; the reason for the LNM was perhaps related to
the greater tumor size. No LNMs were found in patientsal cancers. Nomogram instructions: to obtain the nomogram-predicted risk
line to the points axis to determine howmany points are attributable to each
ints line to assess the patient’s predicted risk of lymph node metastases.
diovascular Surgery c Volume 146, Number 5 1201
FIGURE 3. Frequency of lymph node metastases according to tumor location in submucosal tumors.
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7) when the tumors were larger than 2 cm. Thus, our results
suggest that endoscopic mucosal resection can be
performed for most M3 tumors but that extended 2-field
lymphadenectomy should be considered when the lesion
is larger than 2 cm.
Compared with the lower LNM risk for an intramucosal
lesion, the incidence of LNM increased dramatically when
the cancer had invaded into the submucosa. One major
controversy is whether endoscopic therapy is suitable for
submucosal lesions. Some have considered that selected
SEC tumors less than 2 cm in diameter, with no lymphatic
vessel invasion and well to moderate differentiation can be
treated endoscopically.7,8,15 In our series, only the depth of
tumor invasion and lymphovascular invasion were
identified as independent LNM risk factors. However, theFIGURE 4. Frequency of lymph node metastases according to anatomic
site in submucosal tumors.
1202 The Journal of Thoracic and Cardiovascular Surabsence of any of these factors did not exclude the
possibility of LNM. We also found tumor size, a risk
factor in previous reports,7,16,17 to be of less importance
in the assessment of LNM for submucosal tumors. No
significant difference was found between the incidence of
LNM between smaller tumors (2 cm) and larger tumors
(>2 cm). The comparable incidence of early and skip
metastasis along the abundant lymphatic channels in the
mucosa and submucosa between the smaller and larger
tumors is a possible reason. Consistent with a published
report referring to the issue,18 our data also indicated
that patients should not be recommended for endoscopic
treatment when the cancer has invaded the submucosa.
The optimal extent of lymph node resection for submuco-
sal cancer remains unclear owing to the complex pattern of
LNMs and lack of prospective studies.3,4 To date, few
studies have focused on the pattern of LNM in superficialTABLE 4. Region of lymph node metastases according to tumor
invasion depth
M3
(2 cases)
SM1
(6 cases)
SM2
(10 cases)
SM3
(31 cases)
One region
Neck 1
Mediastinum 1 3 2 14
Abdomen 1 2 5 11
Two regions
Mediastinum plus neck 0 0 0
Abdomen plus neck 0 0 0
Mediastinum plus abdomen 1 3 5
SM, Submucosa.
gery c November 2013
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series reported to determine the pattern of LNMs in
patients with superficial SCC. Most of our patients with
LNMs had only 1 or 2 positive lymph nodes, ranging
from the neck to the upper abdomen. One notable finding
was that the LNMs mostly occurred in the upper
mediastinum, paraesophageal, and perigastric regions.
Paratracheal lymph nodes were the most frequently
involved, followed by paraesophageal and perigastric
nodes; thus, lymph nodes in these areas should be
carefully removed. A second finding was that skip
metastases were common (40.8%). Cervical metastases,
however, were rare. Of the 20 patients with submucosal
cancer who underwent 3-FL, only 1 patient (SM3 cancer,
upper third tumor location) presented with cervical involve-
ment. Therefore, 2-field radical lymphadenectomy
would seem to be sufficient for T1b cancer, although
lymph node resection in the upper mediastinum remains
necessary.
One limitation of the present study was that it was
retrospective. Also, nodal micrometastasis found on immu-
nohistochemistry is common. It has been reported that
almost 27% of patients with superficial SCC with routine
histologically node-negative esophageal cancer (pN0)
will, in fact, be found to harbor nodal micrometastases on
immunohistochemistry,19 although we did not examine
this. In addition, the extent of lymphadenectomy was
affected by the surgical procedure type and surgeon
preference. Thus, lymph nodes in the upper mediastinum
were always omitted when a left thoracotomy was used,
cervical lymphadenectomy was not systematically under-
taken, and the proportion of 3-FL was low. However,
most SEC studies have covered more than a 10-year period,
and our database originated from a single, high-volume
institute within a short period. Thus, our data were more
uniform. Because endoscopic therapy has been performed
increasingly since 2011 at our center, the long-term
survival of patents who underwent endoscopic and surgical
treatment will be reported in future studies.
In conclusion, our results indicate that patients with
cancer limited to the lamina propria mucosa have a low
risk of LNMs. Endoscopic treatment is an appropriate
option for such mucosal cancers, although attention is
needed when the tumor is larger than 2 cm. Because of
the high incidence of LNMs, patients with submucosal
cancer, however, should not be recommended for endo-
scopic treatment. According to the pattern of lymphatic
spread in our study, 2-field radical lymphadenectomy with
careful lymph node resection in the upper mediastinum
should be performed for submucosal SCC.The Journal of Thoracic and CarWe thank Huixun Jia (Department of Biostatistics, Fudan
University Shanghai Cancer Center) for her contribution to the
statistical analysis in our study.References
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